Previous 10 |
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +68%, Pieris Pharmaceuticals (NASDAQ:PIRS) +11%, Molecular Templates (NASDAQ:MTEM) +11%, Paratek Pharmaceuticals (NASDAQ:PRTK) +9%, Capricor Therapeutics CAPR +4%. Losers: Kintara Therapeutics KTRA -19%, Oncon...
The IPO market was full steam ahead this past week as 11 IPOs came to market. SPAC activity remained steady with seven blank check IPOs. New filers continue to pour into the IPO pipeline, with 15 IPOs and eight SPACs submitting initial filings. For further details see: U...
Continuing the trend of solid IPO performances in the healthcare sector today, Definitive Healthcare (DH +47.7%) has surged over 40% on its public debut following a public offering of ~15.6 million shares priced at $27.00 apiece. Definitive Healthcare began trading at about 12.25 PM...
Weakness in Starbucks (NASDAQ:SBUX) and a decline in renamed meme stock highlighted Wednesday's midday trading. For the iconic coffee shop chain, disappointing data out of China weighed on its shares. Meanwhile, Greenidge (NASDAQ:GREE), formerly known as Support.com, saw its value cut by more...
The surgical robotics company Procept BioRobotics (NASDAQ:PRCT) has gained more than 40% on its public debut following an upsized IPO that priced 6.6M shares of the common stock at $25.00 apiece. Tyra (NASDAQ:TYRA) began trading at about 11:59 AM EST at $35.00 per share, implying a premium of...
The IPO market is still on its August break, with just one SPAC pricing. Issuance should resume after Labor Day, and new filers are starting to flood the fall IPO pipeline, with nine initial filings this past week. Five SPACs also submitted initial filings. Waverley Capital Acquis...
News, Short Squeeze, Breakout and More Instantly...
Tyra Biosciences Inc. Company Name:
TYRA Stock Symbol:
OTCMKTS Market:
Tyra Biosciences Inc. Website:
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) PR Newswire - In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein - -TYRA remain...
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights PR Newswire - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 milli...
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors PR Newswire CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnolog...